Identification of gaps in the current allergic rhinitis guidelines and how these can be filled

Ítems similars

• A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
  per: Hellings, Peter, et al.
  Publicat: (2015)
• MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
  per: Scadding, Glenis, et al.
  Publicat: (2015)
• A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
  per: Price, David, et al.
  Publicat: (2013)
• A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
  per: Hellings, Peter, et al.
  Publicat: (2013)
• A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
  per: Bousquet, Jean, et al.
  Publicat: (2013)